# PDE4D

## Overview
PDE4D is a gene that encodes the protein phosphodiesterase 4D, a member of the phosphodiesterase family, which is primarily involved in the hydrolysis of cyclic adenosine monophosphate (cAMP), a crucial second messenger in cellular signaling pathways. The PDE4D protein is characterized by its catalytic domain, which is essential for its enzymatic activity and is regulated by various post-translational modifications and protein-protein interactions. This enzyme plays a significant role in modulating cAMP levels in different tissues, influencing processes such as cardiac function, immune response, and renal water reabsorption. PDE4D's activity is tightly regulated through interactions with other proteins and phosphorylation events, which can either enhance or inhibit its function. Clinically, alterations in PDE4D expression and mutations have been linked to several diseases, including various cancers and acrodysostosis, highlighting its importance as a potential therapeutic target (Zhan2019A; Houslay2001PDE4; Klussmann2016Protein–protein).

## Structure
The PDE4D protein is a member of the phosphodiesterase family, characterized by its ability to hydrolyze cyclic AMP (cAMP). The primary structure of PDE4D consists of a sequence of amino acids that form a catalytic domain with a conserved fold. This domain is composed of approximately 300 amino acids and features sixteen α-helices, forming a tight entity divided into three subdomains (Ke2007Crystal; Lee2002Crystal). The catalytic domain includes a highly conserved pocket with a catalytic metal binding site, crucial for its enzymatic activity (Lee2002Crystal).

PDE4D has several isoforms resulting from alternative splicing, which can affect its regulatory and catalytic properties (Ke2007Crystal). The protein's tertiary structure involves a deep active site pocket, divided into sub-pockets for binding divalent metals and substrates, with zinc and magnesium ions playing essential roles in catalysis (Wang2007Structures). The quaternary structure of PDE4D can involve dimerization, facilitated by an extensive dimerization interface with highly conserved residues (Lee2002Crystal).

Post-translational modifications, such as phosphorylation, can regulate PDE4D activity, with PKA-catalyzed phosphorylation increasing the activity of its isoforms (Cedervall2015Engineered). The regulatory domains, including motifs like calmodulin-binding and GAF, are involved in modulating catalytic activity, although their precise functions are not fully understood (Ke2007Crystal).

## Function
PDE4D (phosphodiesterase 4D) is a cAMP-specific phosphodiesterase that plays a crucial role in regulating intracellular cAMP levels, a key second messenger involved in numerous cellular processes. In healthy human cells, PDE4D is involved in modulating cAMP signaling pathways, which are essential for various physiological functions. It is constitutively active and participates in cAMP hydrolysis, with its activity being modulated by phosphorylation events. For instance, phosphorylation by PKA enhances the activity of long isoforms, while ERK2 phosphorylation inhibits them (Houslay2001PDE4; Klussmann2016Protein–protein).

PDE4D is involved in cardiac function, where it regulates cAMP levels in specific microdomains, such as near the beta-1 adrenergic receptor and the phospholamban/SERCA2 signaling complex. This regulation is crucial for cardiac contractility and response to adrenergic stimulation (Richter2010Conserved). In renal cells, PDE4D helps maintain low cAMP levels on AQP2-bearing vesicles, preventing inappropriate water reabsorption (Klussmann2016Protein–protein).

PDE4D also plays a role in immune cell responses by modulating cAMP levels, which can suppress immune responses like T lymphocyte proliferation (Némoz1996Identification). Its activity is regulated by complex interactions with other proteins, influencing its localization and function within cells (Houslay2001PDE4).

## Clinical Significance
Mutations and altered expression of the PDE4D gene have been implicated in various diseases and conditions. In cancer, PDE4D plays a significant role in tumor progression and prognosis. It is associated with oncogenic activity in several cancers, including CNS tumors, colon cancer, breast cancer, pancreatic cancer, and bladder cancer. Inhibition of PDE4D has been shown to suppress tumor growth in medulloblastoma and induce cell cycle arrest in glioblastoma (Hsien2020PDE4). In colon cancer, elevated PDE4D expression due to underexpression of miR-129-5p leads to oncogenic activity, while its suppression results in cell cycle arrest and apoptosis (Hsien2020PDE4). High PDE4D expression is linked to poor prognosis in pancreatic ductal adenocarcinoma and hepatocellular carcinoma, where it promotes metastasis and tumor growth (Liu2019High; Ragusa2021Phosphodiesterase).

In prostate cancer, PDE4D isoforms exhibit complex roles, with some isoforms being down-regulated in primary and castration-resistant prostate cancer, while others are up-regulated, indicating their potential as diagnostic and prognostic markers (Böttcher2016Human). Additionally, PDE4D mutations are associated with acrodysostosis, a rare congenital disorder characterized by skeletal dysplasia and other systemic features (Zhan2019A). These mutations can lead to increased enzyme activity and decreased cAMP levels, contributing to the disease phenotype (Zhan2019A).

## Interactions
PDE4D, a phosphodiesterase enzyme, is involved in various protein-protein interactions that play critical roles in cellular signaling. PDE4D3, a specific isoform, interacts with mAKAP in the perinuclear compartment, forming a complex with PKA that regulates cardiac myocyte functions. This interaction creates a feedback loop where increased cAMP activates PKA, which phosphorylates PDE4D3 to enhance its activity, thus controlling cAMP-mediated PKA activation (Klussmann2016Protein–protein). PDE4D3 also interacts with AKAP450 at centrosomes and AKAP18δ on AQP2-bearing vesicles in renal cells, maintaining low cAMP levels to prevent inappropriate PKA activation (Klussmann2016Protein–protein).

PDE4D5, another isoform, interacts with β-arrestin and RACK1. These interactions are mutually exclusive, with β-arrestin recruiting PDE4D5 to β-adrenoceptors, contributing to the termination of β-adrenoceptor signaling by hydrolyzing cAMP and inhibiting PKA (Bolger2006Scanning; Klussmann2016Protein–protein). The unique amino-terminal region of PDE4D5 is crucial for its preferential interaction with β-arrestins, which is significant in the context of β2-adrenergic receptor signaling (Lynch2005RNA; Bolger2003The). PDE4D3 also interacts with Ndel1, where phosphorylation by PKA at Ser13 releases PDE4D3, allowing it to interact with other scaffolds like mAKAP (Collins2008Ndel1).


## References


[1. (Zhan2019A) Yongkun Zhan, Weicheng Chen, Zhiyu Feng, Chaozhong Tan, Mengru Li, Yangliu Song, Zhengshan Zhao, Wei Sheng, and Guoying Huang. A novel de novo pde4d gene mutation identified in a chinese patient with acrodysostosis. genesis, September 2019. URL: http://dx.doi.org/10.1002/dvg.23336, doi:10.1002/dvg.23336. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/dvg.23336)

[2. (Richter2010Conserved) Wito Richter, Moses Xie, Colleen Scheitrum, Judith Krall, Matthew A. Movsesian, and Marco Conti. Conserved expression and functions of pde4 in rodent and human heart. Basic Research in Cardiology, 106(2):249–262, December 2010. URL: http://dx.doi.org/10.1007/s00395-010-0138-8, doi:10.1007/s00395-010-0138-8. This article has 110 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00395-010-0138-8)

[3. (Cedervall2015Engineered) Peder Cedervall, Ann Aulabaugh, Kieran F. Geoghegan, Thomas J. McLellan, and Jayvardhan Pandit. Engineered stabilization and structural analysis of the autoinhibited conformation of pde4. Proceedings of the National Academy of Sciences, March 2015. URL: http://dx.doi.org/10.1073/pnas.1419906112, doi:10.1073/pnas.1419906112. This article has 58 citations.](https://doi.org/10.1073/pnas.1419906112)

[4. (Klussmann2016Protein–protein) Enno Klussmann. Protein–protein interactions of pde4 family members — functions, interactions and therapeutic value. Cellular Signalling, 28(7):713–718, July 2016. URL: http://dx.doi.org/10.1016/j.cellsig.2015.10.005, doi:10.1016/j.cellsig.2015.10.005. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2015.10.005)

[5. (Ke2007Crystal) Hengming Ke and Huanchen Wang. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Current Topics in Medicinal Chemistry, 7(4):391–403, February 2007. URL: http://dx.doi.org/10.2174/156802607779941242, doi:10.2174/156802607779941242. This article has 125 citations and is from a peer-reviewed journal.](https://doi.org/10.2174/156802607779941242)

[6. (Bolger2006Scanning) Graeme B. Bolger, George S. Baillie, Xiang Li, Martin J. Lynch, Pawel Herzyk, Ahmed Mohamed, Lisa High Mitchell, Angela McCahill, Christian Hundsrucker, Enno Klussmann, David R. Adams, and Miles D. Houslay. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, β-arrestin and rack1, in camp-specific phosphodiesterase pde4d5. Biochemical Journal, 398(1):23–36, July 2006. URL: http://dx.doi.org/10.1042/bj20060423, doi:10.1042/bj20060423. This article has 133 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20060423)

[7. (Wang2007Structures) Huanchen Wang, Ming-Sheng Peng, Yi Chen, Jie Geng, Howard Robinson, Miles D. Houslay, Jiwen Cai, and Hengming Ke. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochemical Journal, 408(2):193–201, November 2007. URL: http://dx.doi.org/10.1042/bj20070970, doi:10.1042/bj20070970. This article has 94 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20070970)

[8. (Böttcher2016Human) René Böttcher, Kalyan Dulla, Dianne van Strijp, Natasja Dits, Esther I. Verhoef, George S. Baillie, Geert J.L.H. van Leenders, Miles D. Houslay, Guido Jenster, and Ralf Hoffmann. Human pde4d isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. Oncotarget, 7(43):70669–70684, September 2016. URL: http://dx.doi.org/10.18632/oncotarget.12204, doi:10.18632/oncotarget.12204. This article has 21 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.12204)

[9. (Némoz1996Identification) Georges Némoz, RuoBo Zhang, Claudio Sette, and Marco Conti. Identification of cyclic amp‐phosphodiesterase variants from the pde4d gene expressed in human peripheral mononuclear cells. FEBS Letters, 384(1):97–102, April 1996. URL: http://dx.doi.org/10.1016/0014-5793(96)00300-6, doi:10.1016/0014-5793(96)00300-6. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/0014-5793(96)00300-6)

[10. (Hsien2020PDE4) Samuel Hsien Lai, Guston Zervoudakis, Jesse Chou, Mark E. Gurney, and Kelly M. Quesnelle. Pde4 subtypes in cancer. Oncogene, 39(19):3791–3802, March 2020. URL: http://dx.doi.org/10.1038/s41388-020-1258-8, doi:10.1038/s41388-020-1258-8. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-020-1258-8)

[11. (Collins2008Ndel1) Daniel M. Collins, Hannah Murdoch, Allan J. Dunlop, Erik Charych, George S. Baillie, Qi Wang, Friedrich W. Herberg, Nicholas Brandon, Anke Prinz, and Miles D. Houslay. Ndel1 alters its conformation by sequestering camp-specific phosphodiesterase-4d3 (pde4d3) in a manner that is dynamically regulated through protein kinase a (pka). Cellular Signalling, 20(12):2356–2369, December 2008. URL: http://dx.doi.org/10.1016/j.cellsig.2008.09.017, doi:10.1016/j.cellsig.2008.09.017. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.cellsig.2008.09.017)

[12. (Houslay2001PDE4) Miles D Houslay. PDE4 cAMP-specific phosphodiesterases, pages 249–315. Elsevier, 2001. URL: http://dx.doi.org/10.1016/s0079-6603(01)69049-4, doi:10.1016/s0079-6603(01)69049-4. This article has 194 citations.](https://doi.org/10.1016/s0079-6603(01)69049-4)

[13. (Bolger2003The) Graeme B. Bolger, Angela McCahill, Elaine Huston, York-Fong Cheung, Theresa McSorley, George S. Baillie, and Miles D. Houslay. The unique amino-terminal region of the pde4d5 camp phosphodiesterase isoform confers preferential interaction with β-arrestins. Journal of Biological Chemistry, 278(49):49230–49238, December 2003. URL: http://dx.doi.org/10.1074/JBC.M303772200, doi:10.1074/jbc.m303772200. This article has 123 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/JBC.M303772200)

[14. (Lee2002Crystal) Mi Eun Lee, Joseph Markowitz, Jie-Oh Lee, and Hayyoung Lee. Crystal structure of phosphodiesterase 4d and inhibitor complex1. FEBS Letters, 530(1–3):53–58, September 2002. URL: http://dx.doi.org/10.1016/s0014-5793(02)03396-3, doi:10.1016/s0014-5793(02)03396-3. This article has 91 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0014-5793(02)03396-3)

[15. (Liu2019High) Fude Liu, Jieyi Ma, Kebing Wang, Zhi Li, Qingping Jiang, Hui Chen, Wen Li, and Jintang Xia. High expression of pde4d correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma. Journal of Cancer, 10(25):6252–6260, 2019. URL: http://dx.doi.org/10.7150/jca.35443, doi:10.7150/jca.35443. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/jca.35443)

[16. (Lynch2005RNA) Martin J. Lynch, George S. Baillie, Ahmed Mohamed, Xiang Li, Charlotte Maisonneuve, Enno Klussmann, Gino van Heeke, and Miles D. Houslay. Rna silencing identifies pde4d5 as the functionally relevant camp phosphodiesterase interacting with βarrestin to control the protein kinase a/akap79-mediated switching of the β2-adrenergic receptor to activation of erk in hek293b2 cells. Journal of Biological Chemistry, 280(39):33178–33189, September 2005. URL: http://dx.doi.org/10.1074/jbc.m414316200, doi:10.1074/jbc.m414316200. This article has 177 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m414316200)

[17. (Ragusa2021Phosphodiesterase) Federica Ragusa, Nadia Panera, Silvia Cardarelli, Marco Scarsella, Marzia Bianchi, Stefano Biagioni, Mauro Giorgi, Anna Alisi, and Mara Massimi. Phosphodiesterase 4d depletion/inhibition exerts anti-oncogenic properties in hepatocellular carcinoma. Cancers, 13(9):2182, May 2021. URL: http://dx.doi.org/10.3390/cancers13092182, doi:10.3390/cancers13092182. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13092182)